Larimar Therapeutics, Inc. (LRMR) - Form 8-K Summary
Business Context and Reporting Period
Date of Report: May 28, 2020 (Events reported May 28–29, 2020)
Company: Larimar Therapeutics, Inc. (formerly Zafgen, Inc.)
Key Event: Completion of a business combination with Chondrial Therapeutics, Inc. via a reverse merger, accompanied by a 1-for-12 reverse stock split and a name change. The company is now a clinical-stage biotechnology firm focused on rare diseases using cell-penetrating peptide technology.
Key Financial Metrics and Liquidity
- Private Placement Proceeds: Gross proceeds of $80 million; net proceeds of $75.5 million from the sale of 6,105,359 shares and 628,403 pre-funded warrants at approximately $11.88 per unit.
- Cash Position: Approximately $116 million in cash on a post-merger basis (combining Zafgen's ~$40 million and new proceeds).
- Debt Repayment: Paid off and terminated all liabilities under a loan agreement with Silicon Valley Bank, totaling approximately $13.2 million in cash.
- Outstanding Shares: Approximately 15.3 million shares of Common Stock outstanding immediately following the merger and private placement.
- Operating Obligations: Retained an office lease with total payment obligations of approximately $9 million; actively seeking to sublease.
Material Changes vs. Prior Period
- Corporate Structure: Zafgen, Inc. merged with Chondrial Therapeutics, Inc. Chondrial survives as a wholly-owned subsidiary. The company name changed to Larimar Therapeutics, Inc.
- Capital Structure: Executed a 1-for-12 reverse stock split. Issued new equity to Chondrial shareholders (approx. 66% ownership post-merger, pre-placement) and private placement investors (approx. 40% ownership post-placement).
- Leadership: Former Zafgen CEO Jeffrey Hatfield and CFO Patricia Allen resigned. Carole Ben-Maimon, M.D. (former Chondrial CEO) appointed President and CEO. Michael Celano appointed CFO.
- Board Composition: Board size reduced from eight to seven members. New directors appointed include Joseph Truitt (Chairman), Carole Ben-Maimon, Thomas Hamilton, and Jonathan Leff.
Guidance, Outlook, and Risks
- Use of Proceeds: Net proceeds from the private placement will fund research and development of product candidates, working capital, and general corporate purposes.
- Lock-Up Restrictions: Approximately 71.1% of common stock outstanding immediately after the merger is subject to 180-day lock-up restrictions.
- Registration Rights: The company must file a Form S-3 registration statement within 30 days of the closing to register shares sold in the private placement. Failure to do so may trigger liquidated damages.
- Financial Reporting: Pro forma financial information and financial statements for Chondrial are to be filed in an amendment to this 8-K within 71 calendar days.
Investor Verification Checklist
- Verify the final pro forma cash position and burn rate in the upcoming 8-K/A filing (due within 71 days).
- Confirm the effectiveness of the Form S-3 registration statement for the private placement shares within the 30-day deadline.
- Monitor the status of the office lease subletting efforts to mitigate the $9 million obligation.
- Review the specific vesting schedules and exercise prices for the new executive equity awards (e.g., CFO Michael Celano's option grant).
- Check for any updates on the clinical pipeline status of Chondrial's cell-penetrating peptide platform.